Covered recipient · General Payments record
ROUBA GARRO
Allopathic & Osteopathic Physicians Pediatrics Pediatric Nephrology
General Payments · PY2018–2024
$6,908.02
- Reported across 19 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $5,225.00 | 1 |
| Travel and Lodging | $1,073.97 | 5 |
| Food and Beverage | $333.79 | 6 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Amgen Inc. | $6,592.70 | 11 |
| Takeda Pharmaceuticals U.S.A., Inc. | $40.06 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (12)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Amgen Inc. | $149.99 | 04/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115649386 | CMS |
| Amgen Inc. | $175.00 | 04/11/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1115649420 | CMS |
| Amgen Inc. | $23.96 | 04/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115649366 | CMS |
| Amgen Inc. | $175.00 | 04/12/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1115649374 | CMS |
| Amgen Inc. | $204.06 | 04/12/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1115649380 | CMS |
| Amgen Inc. | $23.96 | 04/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115649394 | CMS |
| Amgen Inc. | $43.12 | 04/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115649402 | CMS |
| Amgen Inc. | $52.70 | 04/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115649412 | CMS |
| Amgen Inc. | $436.19 | 04/12/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1115649429 | CMS |
| Amgen Inc. | $83.72 | 04/12/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1115649438 | CMS |
| Amgen Inc. | $5,225.00 | 04/12/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1115649446 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $40.06 | 09/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1137552706 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.